The randomized controlled trial of the efficacy of mecobalamin and lafutidine after goshajinkigan administered in breast cancer patients with chemotherapy-induced peripheral neuropathy.
Phase 3
- Conditions
- chemotherapy-induced peripheral neuropathy
- Registration Number
- JPRN-UMIN000011007
- Lead Sponsor
- Department of breast and endocrine surgery, Meiwa Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
1)not goshajinkigan administered 2)with severe complications (such as liver failure, renal failure, heart failure) 3)with history of allergy 4)alredy adminstered with Goshajinkigan, Mecobalamin or Lafutidine. 5)with peripheral neuropathy for other cause (such as diabetes) 6)receiving drugs to influence peripheral neuropathy 7)doctore's decision not to be registered to this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The level of improvement of peripheral neuropathy is evaluated by Visual Analogue Scale (VAS).
- Secondary Outcome Measures
Name Time Method Safety